If you’ve ever ordered a pharmaceutical intermediate, you’ve likely received a COA (certificate of analysis) and a set of storage guidelines scrawled on the back of it. But if you’ve ever watched a batch of a key intermediate degrade in a warehouse, or had a client reject a shipment because it arrived with a higher impurity level than specs allowed, you know those guidelines aren’t just arbitrary fine print. As a pharmaceutical intermediates supplier who’s spent the last dozen years calibrating temperature monitors, retesting shelf lives for new API intermediates, and troubleshooting unstable shipments, I can tell you stability isn’t a single number—it’s the backbone of the work we do to keep our clients’ drug development timelines on track and patients safe. Pharmaceutical Intermediates
Let me start with a quick, messy story from early in my career. I was working for a small CRO that supplied intermediates to a handful of mid-sized biotechs, and we’d just filled a 25kg drum of a common amide intermediate used in oncology drug development. We shipped it cross-country in a standard industrial shipping container, no temperature control, because the product’s COA noted it was “stable at ambient temperature.” A week later, the client called us screaming—their HPLC tests showed 0.8% of a related degradation product that wasn’t in our release testing. By the time we pulled the drum from their warehouse and tested it ourselves, that level had climbed to 1.2%, just over their 1.0% acceptance limit. It turned out that the local temperature in their warehouse had spiked to 38°C (100°F) three days in a row, a side effect of a broken AC unit no one had noticed. We ate the cost of the return and re-shipment, and I spent the next six months auditing every stability study we ran, every storage note we sent, and every shipping protocol we used. That mistake taught me that stability conditions aren’t just what works in a lab—they’re tailored to the intermediate’s chemical structure, the impurities it forms, and the real-world conditions it will face between our facility and our client’s lab or warehouse.
First, there’s chemical stability, the most familiar part of the equation. Every intermediate has a molecular structure, and that structure dictates how it reacts with its environment. Take that amide intermediate I mentioned: amides are generally stable, but under acidic or basic conditions, even mild ones, they can hydrolyze—split apart when exposed to water. That drum we shipped had absorbed a small amount of moisture through the packaging over the trip, and the elevated temperature sped up that hydrolysis into the related acid impurity. Other common reactions for intermediates include oxidation, especially for compounds with double bonds or sulfur atoms; photodegradation, where UV light breaks molecular bonds; and racemization, where a chiral center (a carbon atom bonded to four different groups, the part that makes a molecule biologically active) flips, turning an active drug intermediate into an inactive one.
To test chemical stability, we run forced degradation studies—we expose small samples of the intermediate to extreme conditions to see how it breaks down. We’ll test it in 1M hydrochloric acid for 24 hours, in 1M sodium hydroxide, at 60°C, under bright UV light, even at high humidity. For each test, we measure the rate at which parent compound disappears and impurities appear. If an intermediate breaks down rapidly at 50°C, we know it needs refrigerated storage. If it’s sensitive to light, we package it in amber glass or opaque plastic. If it hydrolyzes easily, we use moisture-resistant packaging with desiccants. For that amide intermediate, our forced degradation studies showed it only hydrolyzes quickly above 30°C, so we adjusted our shipping: we now use insulated containers with ice packs for shipments during hot months, and we update our COAs to explicitly note “stable for up to 7 days at <25°C” instead of the vague “ambient temperature” we’d used before.
Next, there’s physical stability, which is often overlooked but just as critical. Physical stability refers to how the intermediate behaves as a solid or a liquid, which can change even if its molecular structure stays the same. For solid intermediates, common physical issues are polymorphism (the same molecule forming different crystal structures), hygroscopicity (absorbing moisture from the air), and caking (clumping together into a solid block). For liquid intermediates, it can be separation into layers, viscosity changes, or even crystallization of solid parts out of the liquid.
I once had another incident with a liquid intermediate: a cyclic amine used in antibiotic development. Our client ordered 50L of it, and when it arrived, they said it had separated into two cloudy layers, making it impossible to use in their reaction. When we tested our sample from the same batch, it was a single clear liquid, so we knew the problem was physical, not chemical. It turned out the client had stored the drum in a cold basement, well below the intermediate’s melting point, so parts of it crystallized and separated. Physical stability is tied to temperature just as much as chemical stability, but it’s not about reaction rates—it’s about how molecules arrange themselves. For hygroscopic intermediates, caking can make it hard to measure accurate weights for reactions, which ruins yields and leads to inconsistent API production. For polymorphic intermediates, different crystal forms can have different solubility, which can make them harder to dissolve in a client’s reaction, leading to low conversion rates. We now test every intermediate for physical stability at our in-house analytical lab, running XRPD (X-ray powder diffraction) to check for polymorphs, moisture sorption isotherms to measure hygroscopicity, and freezing point tests to set clear storage temperature ranges. That cyclic amine intermediate, for example, is stable between 10°C and 40°C, so we now add temperature-controlled shipping for any order being sent to a location where temperatures could drop below that threshold.
The third, and often most overlooked, layer of stability is process stability. This is how the intermediate behaves when a client uses it in their drug development process, not just how it sits on a shelf. A client might release an intermediate that meets our COA specs, but if their process uses high temperatures, harsh reagents, or long reaction times, the intermediate might degrade during their reaction, leading to low API yields or unwanted byproducts. That’s why good suppliers don’t just send a batch and wash their hands of it—we work with our clients to help them account for process stability too. For example, if a client is using a chiral intermediate in a reaction that runs at 80°C for 12 hours, we can provide them with stability data for that intermediate under those exact reaction conditions, so they know how much to use to account for any degradation during the process. We also include information on how to handle the intermediate: when to dissolve it, how long it can sit in solution before use, even what type of solvent is best for storage or reaction to avoid degradation. A lot of clients don’t think to test their intermediates under process conditions, so providing that data is part of what makes a good supplier reliable.
Now, let’s talk about how we verify stability over time, because even if we run all those studies before shipment, that doesn’t mean the intermediate will stay stable for its entire shelf life. We use long-term stability studies and accelerated stability studies to set shelf lives. Accelerated studies are run at higher temperatures and humidity—usually 40°C and 75% relative humidity—so we can get data in a few months instead of two years. We use that data to predict how the intermediate will behave over time at real storage conditions. Long-term studies are run at the intermediate’s recommended storage conditions, usually 25°C and 60% relative humidity, and we test samples every three, six, nine, and twelve months, then annually after that. For intermediates with a shelf life longer than two years, we’ll pull samples from long-term studies every six months to track changes.
It’s worth noting that regulatory bodies—like the FDA, ICH, and EMA—have guidelines for stability testing for pharmaceutical intermediates, and we strictly follow those. ICH Q7, the guide for good manufacturing practices for active pharmaceutical ingredients, has a whole section on stability testing for intermediates and starting materials. They require us to test for the same impurities we test for in release, and to set expiration dates based on data, not guesswork. That’s why we don’t just pick a 2-year shelf life for every intermediate—each one is different. For our oncology amide intermediate, for example, our long-term stability studies show no significant degradation over 36 months at <25°C, so we set a 3-year shelf life. For that moisture-sensitive sulfonyl chloride intermediate we supply, which oxidizes easily if exposed to water, our stability studies show it only stays stable for 18 months at 20°C, so we set a 1.5-year shelf life and tell clients to store it in a freezer at -20°C if they won’t use it within that time.
Another thing I want to talk about is packaging, because packaging is the last line of defense for stability. A lot of suppliers skimp on packaging to cut costs, but that’s a mistake. For intermediates sensitive to moisture, we use double-layered polyethylene bags inside steel drums, with a desiccant sachet placed in each bag. For light-sensitive intermediates, we use amber glass bottles or aluminum-lined drums. For solids prone to caking, we add an anti-caking agent that’s approved for pharmaceutical use, or we package them in breathable liners that let any trapped moisture escape. We also label every package with clear storage instructions, expiration date, and a batch number, so clients can trace the batch back to our manufacturing records if they have any issues.
I’ve seen a lot of issues where bad packaging leads to stability problems. A client once told us a batch of a high-purity solid intermediate had turned yellow, a sign of oxidation, and when we checked our records, we saw the packaging for that batch had a small tear in the outer drum that our quality control team missed. That’s why we do 100% packaging inspections before we ship anything, not just random samples. We also use tamper-evident seals on every package, so if a client receives a package with a broken seal, they know it might have been exposed to the wrong conditions and can test it before using it.
At the end of the day, all this work around stability isn’t just about meeting specs or avoiding mistakes—it’s about supporting our clients’ work to develop safe, effective drugs. Every intermediate we supply is a building block for something that will eventually reach a patient, so making sure that building block is pure and stable is non-negotiable. When a biotech team is testing a new drug for a rare disease, they don’t have extra time or extra money to deal with a batch of intermediate that degrades halfway through their process. When a large pharma company is running a clinical trial, they need consistent, reliable intermediates to ensure their trial data is valid.
That’s why we don’t just sell pharmaceutical intermediates—we offer stability expertise. We work closely with each client to understand their specific needs: if they’re shipping to a remote clinic in a hot climate, we’ll recommend insulated packaging and shorter lead times. If they’re working with a chiral intermediate, we’ll provide data on stereochemical stability so they can maintain the correct ratio of active isomer. If they have questions about storage or handling, our technical team is available to walk them through it, no matter how small the question.
If you’re working on a drug development project, whether you’re a small biotech just starting out or a large pharma company scaling up production, stability should be top of mind when choosing a pharmaceutical intermediates supplier. Don’t just go for the lowest price—ask about their stability testing protocols, their shelf life data, their packaging practices, and how they support clients with process stability. A reliable supplier will be transparent about their data, happy to share stability reports, and willing to collaborate with you to find the right conditions for your specific intermediate.
Boric Acid Intermediates If you’re looking for a partner that prioritizes stability at every step, feel free to reach out to discuss your intermediate needs. We’re here to help you keep your projects on track, from lab-scale development to large-scale commercial production.
References
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Q7(R1): Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. 2000.
- United States Food and Drug Administration (FDA). Guidance for Industry: Stability Testing of Drug Substances and Drug Products. 2003.
- Pikal MJ, et al. Physical Stability of Pharmaceutical Solids. Journal of Pharmaceutical Sciences. 1997;86(10):1125-1137.
- Singh R, et al. Forced Degradation Studies: A Review. International Journal of Pharmaceutical Sciences and Research. 2011;2(5):1171-1182.
Hubei Jiutian Bio-medical Technology Co., Ltd.
Hubei Jiutian Bio-medical Technology Co., Ltd. is one of the most professional pharmaceutical intermediates manufacturers and suppliers in China, also supports customized service with low price. Please feel free to buy bulk cheap pharmaceutical intermediates made in China here from our factory. For free sample, contact us now.
Address: Room 105, Building 1, Zhongchuang Tower, No. 2 Darui Road, Guandong Industrial Park, Wuhan East Lake High-Tech Development Zone
E-mail: info@jiutian-bio.com
WebSite: https://www.jiutian-bio.com/
